Effectiveness of Oral Nirmatrelvir/Ritonavir vs. Intravenous Three-Day Remdesivir in Preventing Progression to Severe COVID-19: A Single-Center, Prospective, Comparative, Real-Life Study

Background: Nirmatrelvir/ritonavir (NMV/r) and three-day course remdesivir (3RDV) have been approved as early treatments for COVID-19 outpatients not requiring supplemental oxygen. Real-life data on the efficacy of antivirals among immunocompromised patients or directly comparing their effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales: Basoulis, Dimitrios, Tsakanikas, Aristeidis, Gkoufa, Aikaterini, Bitsani, Aikaterini, Karamanakos, Georgios, Mastrogianni, Elpida, Georgakopoulou, Vasiliki E., Makrodimitri, Sotiria, Voutsinas, Pantazis-Michail, Lamprou, Panagiota, Kontos, Athanasios, Tsiakas, Stathis, Gamaletsou, Maria N., Marinaki, Smaragdi, Sipsas, Nikolaos V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383489/
https://www.ncbi.nlm.nih.gov/pubmed/37515201
http://dx.doi.org/10.3390/v15071515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383489/
https://www.ncbi.nlm.nih.gov/pubmed/37515201
http://dx.doi.org/10.3390/v15071515

Ejemplares similares